PL1976522T5 - Kompozycja farmaceutyczna zawierająca montelukast - Google Patents

Kompozycja farmaceutyczna zawierająca montelukast

Info

Publication number
PL1976522T5
PL1976522T5 PL06830764T PL06830764T PL1976522T5 PL 1976522 T5 PL1976522 T5 PL 1976522T5 PL 06830764 T PL06830764 T PL 06830764T PL 06830764 T PL06830764 T PL 06830764T PL 1976522 T5 PL1976522 T5 PL 1976522T5
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
containing montelukast
montelukast
pharmaceutical
Prior art date
Application number
PL06830764T
Other languages
English (en)
Other versions
PL1976522T3 (pl
Inventor
Vesna Kroselj
Renata Osolnik
Turk Urska
Bevec Franci
Original Assignee
Krka Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1976522(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP05113112A external-priority patent/EP1803457A1/en
Application filed by Krka Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka Tovarna Zdravil, D.D., Novo Mesto
Publication of PL1976522T3 publication Critical patent/PL1976522T3/pl
Publication of PL1976522T5 publication Critical patent/PL1976522T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06830764T 2005-12-30 2006-12-20 Kompozycja farmaceutyczna zawierająca montelukast PL1976522T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05113112A EP1803457A1 (en) 2005-12-30 2005-12-30 Pharmaceutical composition containing montelukast
EP06116654 2006-07-05
EP06830764.4A EP1976522B2 (en) 2005-12-30 2006-12-20 Pharmaceutical composition containing montelukast
PCT/EP2006/070045 WO2007077135A1 (en) 2005-12-30 2006-12-20 Pharmaceutical composition containing montelukast

Publications (2)

Publication Number Publication Date
PL1976522T3 PL1976522T3 (pl) 2013-11-29
PL1976522T5 true PL1976522T5 (pl) 2019-12-31

Family

ID=37734296

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06830764T PL1976522T5 (pl) 2005-12-30 2006-12-20 Kompozycja farmaceutyczna zawierająca montelukast

Country Status (7)

Country Link
EP (1) EP1976522B2 (pl)
EA (1) EA021960B1 (pl)
ES (1) ES2426443T3 (pl)
PL (1) PL1976522T5 (pl)
PT (1) PT1976522E (pl)
SI (1) SI1976522T2 (pl)
WO (1) WO2007077135A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CN102046202A (zh) * 2008-03-26 2011-05-04 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
TR201009398A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
CN103040784A (zh) * 2012-12-26 2013-04-17 深圳致君制药有限公司 一种孟鲁司特钠片组合物及其制备方法
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
WO1997016173A1 (en) 1995-11-02 1997-05-09 Merck Frosst Canada Inc. New technology for wet granulation
DK1283036T3 (da) * 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
AU2003209043A1 (en) 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
CA2477260C (en) * 2002-03-12 2009-05-19 Microdose Technologies, Inc. Site specific delivery of co-administered drugs via inhalation
US20040265375A1 (en) † 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
CA2528228C (en) 2003-06-06 2011-09-20 Morepen Laboratories Limited A method for the preparation of montelukast acid and sodium salt thereof in amorphous form
AU2004283832B2 (en) 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
EP3366283B1 (en) 2004-01-20 2021-09-01 Novartis AG Direct compression formulation and process
WO2005075427A2 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
CN1287792C (zh) 2004-08-30 2006-12-06 鲁南制药集团股份有限公司 孟鲁司特钠的分散片剂型
AU2005299490C1 (en) * 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
ITMI20050247A1 (it) 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
WO2007012075A2 (en) 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast

Also Published As

Publication number Publication date
PL1976522T3 (pl) 2013-11-29
EP1976522B2 (en) 2019-07-03
EA200801614A1 (ru) 2008-10-30
SI1976522T2 (sl) 2019-11-29
ES2426443T3 (es) 2013-10-23
EP1976522B1 (en) 2013-06-05
EA021960B1 (ru) 2015-10-30
PT1976522E (pt) 2013-09-09
WO2007077135A1 (en) 2007-07-12
EP1976522A1 (en) 2008-10-08
SI1976522T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
ZA200708580B (en) Composition containing anti-dementia drug
GB0513692D0 (en) Novel pharmaceutical compositions
IL194242A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
PL1884242T3 (pl) Kompozycja farmaceutyczna zawierająca lurasidon
EP1909576A4 (en) NEW PHARMACEUTICAL COMPOUNDS
ZA200708705B (en) Pharmaceutical composition
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
PL2005958T3 (pl) Kompozycja farmaceutyczna do stosowania zewnętrznego
IL188352A0 (en) Pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
IL185602A0 (en) Pharmaceutical compositions containing acarbose
IL192091A0 (en) Pharmaceutical compositions
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
GB0404420D0 (en) Pharmaceutical composition
SI1976522T2 (sl) Farmacevtski sestavek, ki vsebuje montelukast
GB0522045D0 (en) Pharmaceutical compositions
GB0425255D0 (en) Pharmaceutical composition
GB0525093D0 (en) Veterinary composition
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
GB0514259D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939
GB0402799D0 (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition
GB0518166D0 (en) Pharmaceutical composition